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Pharmacologic therapy for peripheral arterial
disease and claudication
William R. Hiatt, MD, Denver, Colo
Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis that is associated with a high risk
of cardiovascular mortality and significant limitation in function because of limb ischemia. Patients with PAD should be
considered to have significant coronary and cerebral arterial disease that requires aggressive risk factor management,
including the prescription of antiplatelet drugs, to lower the subsequent risk of myocardial infarction, stroke, and death.
In the population with PAD, level 1 and level 2 evidence supports the use of statin drugs for lipid management,
angiotensin-converting enzyme-1 inhibitors for blood pressure control, and aspirin or clopidogrel as antiplatelet agents.
Once this is accomplished, the severity of limb symptoms should be assessed, and a structured exercise program or the
selected use of drugs such as cilostazol to treat claudication should be prescribed. In patients primarily considered for
surgical treatment, antiplatelet and anticoagulant drug therapy can be used as a means of promoting graft patency, and
beta-adrenergic blockers can be used as a means of reducing the perioperative risks associated with vascular surgery. (J
Vasc Surg 2002;36:1283-91.)
Peripheral arterial occlusive disease (PAD) of the lower
extremities is one of the major manifestations of systemic
atherosclerosis. The age-adjusted prevalence rate of PAD is
approximately 12%, and the disorder affects men and
women equally.1,2 The risk of the disease increases 2- to
3-fold for every 10-year increase in age after the age of 40
years, and PAD is highly associated with cardiovascular risk
factors such as cigarette smoking, diabetes mellitus, hyper-
lipidemia, hypertension, and increases in homocysteine lev-
els.2-4 The most important of these risk factors are diabetes
mellitus and smoking, each with a relative risk for PAD of 3-
to 4-fold.2,3
PAD is highly associated with critical coronary and
carotid artery diseases that predispose these patients to a
marked increase risk of myocardial infarction, ischemic
stroke, and vascular death.5 For example, in patients with
PAD, the adjusted all-cause mortality risk rate is increased
3-fold, and the cardiovascular mortality rate is increased
6-fold.6 This risk is approximately equal in men and women
and remains elevated even when the patient had no earlier
clinical evidence of cardiovascular disease.7,8 With increas-
ing severity of PAD, as measured by means of the ankle-
brachial index, there is a concomitant increased risk of
myocardial infarction, ischemic stroke, and vascular
death.9,10 Therefore, a primary goal of pharmacotherapy
for this disorder is the aggressive management of cardiovas-
cular risk factors to prevent the progression of leg arterial
disease and also to reduce the risk of ischemic events.
Related to these goals is the importance of antiplatelet
therapy and angiotensin-converting enzyme (ACE) inhib-
itor drugs, which also have a significant benefit in reducing
the systemic cardiovascular risk.
The limb manifestations of PAD principally fall into the
categories of chronic stable claudication, critical leg isch-
emia, and, rarely, acute limb ischemia. In the patient with
claudication, the principal symptomatic treatments include
smoking cessation, supervised exercise therapy, and the
selected use of drugs to improve exercise tolerance and
walking distance. Patients with critical leg ischemia require
restoration of blood flow to heal wounds, relieve ischemic
pain, and prevent limb loss. In this situation, pharmaco-
therapy may be seen as an adjuvant to the primary treat-
ment modality of revascularization.
Important roles for non-operative therapy in the sub-
group of patients undergoing vascular surgery are the pre-
vention of cardiac ischemic events during the operative
procedures and the promotion of the long-term patency of
bypass grafts. In this regard, the use of beta-adrenergic
blockers and other risk-reduction therapies may decrease
the perioperative risk of vascular surgery. In addition, this
article will discuss the role of anticoagulation and antiplate-
let therapy in maintaining graft patency. Recommendations
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for drug therapy in this article are made on the basis of data
from randomized controlled trials involving large sub-
groups of patients with PAD or from randomized trials in




Patients with PAD typically have multiple cardiovascu-
lar risk factors, which puts them at a markedly increased risk
for cardiovascular events. Also, a reduced blood pressure in
the ankle indicates extensive systemic vascular disease,
which is an independent risk factor for cardiovascular
events. Thus, current recommendations from numerous
consensus documents are used as a means of identifying
patients with PAD as a high-risk population worthy of
intensive risk-factor modification. In this section, an ap-
proach to each of the major risk factors of this disorder will
be discussed.
Smoking cessation. Cigarette smoking is associated
with a marked increased risk for peripheral atherosclero-
sis.2,11,12 The number of pack years is associated with
disease severity, an increased risk of amputation, peripheral
graft occlusion, and mortality.13,14 When evaluated with
treadmill testing, patients with PAD who smoked had more
severe claudication pain and a decreased peak exercise
performance compared with patients who did not smoke.15
Because of these associations, smoking cessation has been a
cornerstone of the management of PAD. Although advice
to stop smoking is associated with modest smoking cessa-
tion rates, pharmacologic therapy, including nicotine re-
placement and antidepressant drug therapy, can assist in
smoking cessation.16 Nicotine replacement can be achieved
with a patch or gum and has been shown to increase
cessation rates.17,18 Certain classes of antidepressant drugs
facilitate quitting in patients who smoke and are also de-
pressed, but the drug bupropion has been shown to be
effective in all patients who smoke.19-21 Thus, a practical
approach would be to combine behavior modification,
nicotine replacement therapy, and bupropion to achieve
the best cessation rates.
The role of smoking cessation in treating the symptoms
of claudication is not as clear, and studies have not consis-
tently shown that smoking cessation is associated with an
improved walking distance.22,23 Therefore, patients should
be encouraged to stop smoking primarily as a means of
reducing their systemic risk and their risk of progression to
amputation, but improved symptoms should not be prom-
ised immediately with cessation.
Hyperlipidemia. Independent risk factors for PAD
include elevations of total cholesterol, low-density lipopro-
tein (LDL) cholesterol, triglycerides, and lipoprotein(a)
levels.2,24,25 Increases in high-density lipoprotein choles-
terol and apolipoprotein(a-1) levels are protective against
PAD.24 Current recommendations for the management of
lipid disorders in PAD are the achievement of an LDL
cholesterol level 100 mg/dL and the modulation of the
increased triglyceride and low high-density lipoprotein pat-
tern.26 However, these recommendations were made on
the basis of small trials on PAD that focused on surrogate
end points and extrapolation from large randomized trials
in patients with coronary artery disease.27,28 Subgroup
analyses of these large trials in patients with coronary artery
disease also demonstrated that aggressive lipid-lowering
was associated with a decreased risk of developing claudi-
cation or an absent femoral pulse.29
Until recently, there has been no direct evidence of the
mortality benefits of treating patients who have PAD with
statin drugs. Thus, data from the Heart Protection study
(HPS) are an important addition to understanding the role
of lowering LDL cholesterol levels in this population.30
The HPS enrolled20,500 subjects who were at high risk
for cardiovascular events, including 6748 patients with
PAD. Many of these subjects had low baseline cholesterol
levels. Patients were randomized to receive 40 mg of sim-
vastatin, antioxidant vitamins (vitamin E, vitamin C, and
beta-carotene), a combination of treatments, or placebo by
using a 2  2 factorial design, with a 5-year follow-up
period. Simvastatin (40 mg) was associated with a 12%
reduction in total mortality rate, a 17% reduction in vascu-
lar mortality rate, a 24% reduction in coronary heart disease
events, a 27% reduction in all strokes, and a 16% reduction
in non-coronary revascularizations. Similar results were
obtained in the subgroup of patients with PAD, whether
they had evidence of coronary disease at baseline or not.
Further, there was no threshold cholesterol value below
which statin therapy was not associated with a benefit. In
contrast, there was no benefit (or harm) with the use of
antioxidant vitamins in the prevention of ischemic events.30
Thus, the HPS demonstrated that in patients with PAD
(even in the absence of an earlier myocardial infarction or
stroke), aggressive LDL cholesterol-lowering therapy was
associated with a marked reduction in cardiovascular events
(myocardial infarction, stroke, and vascular death). This is
the first large, randomized trial of statin therapy to demon-
strate that aggressive lipid modification can significantly
improve outcomes in patients with PAD. A limitation of the
HPS was that the evidence in PAD was derived from a
subgroup analysis, and we still do not have a trial exclusively
evaluating patients with PAD. Despite these limitations, all
patients with PAD should have their LDL cholesterol levels
lowered to 100 mg/dL.
Hypertension. Hypertension is an independent risk
factor for PAD that is associated with a 2- to 3-fold in-
crease.2,12,25 Guidelines also support the aggressive treat-
ment of blood pressure in patients with atherosclerosis,
indicating that patients with PAD are in a high-risk group,
with a treatment goal of 130/85 mm Hg.31 Beta-adrener-
gic blocking drugs have previously been considered to be
contraindicated for PAD because of the possibility of wors-
ening claudication symptoms.32 However, this concern has
not been borne out with randomized trials, and thus beta-
adrenergic blockers drugs can be used in patients with
claudication.33,34 In particular, patients with PAD who also
have concomitant coronary disease may have additional
cardioprotection with beta-adrenergic blocking agents.
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Therefore, this should be considered to be a viable drug
class for these patients.
The ACE inhibitor drugs have also shown benefit be-
yond blood pressure-lowering in high-risk groups, specifi-
cally with results from the Heart Outcomes Prevention
Evaluation study of 4046 patients with PAD.35 In this
subgroup, there was a 22% risk reduction in patients ran-
domized to receive ramipril compared with patients ran-
domized to receive a placebo, and this reduction was inde-
pendent of the lowering of blood pressure. On the basis of
this finding, the Food and Drug Administration (FDA) has
now approved ramipril for its cardioprotective benefits in
patients at high-risk, including patients with PAD. Thus, as
a drug class, the ACE inhibitors would certainly be recom-
mended in these patients.
Diabetes mellitus. Diabetes mellitus increases the
risk of PAD approximately 3-fold and the risk of claudica-
tion 3- to 5-fold.2,36 In addition, diabetes mellitus is also
associated with peripheral neuropathy and skin infections,
which lead to an increased risk of foot ulcers. Although
diabetes mellitus is highly associated with peripheral ath-
erosclerosis, the degree of glycemic control does not pre-
dict the severity of the peripheral atherosclerosis.37 These
observations suggest that diabetes mellitus is a critical risk
factor for PAD primarily in conjunction with other cardio-
vascular risk factors.
Several studies of both type 1 and type 2 diabetes
mellitus have shown that aggressive blood sugar-lowering
can prevent microvascular complications (particularly reti-
nopathy), but not cardiovascular disease, including
PAD.38,39 Thus, although the current American Diabetes
Association recommended goal for treatment of diabetes
mellitus is hemoglobin A1C of 7%, it is unclear whether
achieving this goal will protect the peripheral circulation.
Homocysteine. Elevated plasma homocysteine levels
are an independent risk factor for PAD.40,41 Although
B-vitamin supplements can lower homocysteine levels, the
benefits in preventing cardiovascular events are lacking.42
Inflammation. Markers of inflammation have been
associated with the development of atherosclerosis and
cardiovascular events. In particular, C-reactive protein
(CRP) is independently associated with PAD, even in pa-
tients with normal lipid levels.43,44 In the Physician’s
Health Study, an elevated CRP level was a risk factor for the
development of symptomatic PAD and also a risk for pe-
ripheral revascularization.45 The measurement of CRP may
also guide lipid therapy because statin drugs lower CRP
levels, and the reduction in CRP levels may contribute to
the benefits of statin drugs.46
Modulation of endothelial function. The formation
of nitric oxide is critical in maintaining normal endothelial
function, and alterations in endothelial function are well
described in patients with atherosclerosis. In patients with
PAD, nitric oxide synthesis can be inhibited by the endog-
enous compound asymmetrical dimethylagrinine
(ADMA). The levels of ADMA in patients with PAD are
directly correlated with the inhibition of nitric oxide syn-
thesis and the severity of claudication symptoms.47 Poten-
tially, this inhibition in nitric oxide synthesis can be re-
versed by means of dietary supplementation with
L-arginine. In addition, vitamin C supplementation has
been shown to inhibit the breakdown of nitric oxide,
resulting in improved endothelial function.48 In 1 trial of
PAD, antioxidant therapy was associated with a trend of a
reduction in cardiovascular events.49 However, the HOPE
trial and the HPS trial did not confirm these results.50
Hypercoagulable states. Alterations in coagulation
are commonly associated with the development of venous
thrombosis and thromboembolism. However, with the
exception of changes in homocysteine metabolism, hyper-
coagulable states have been evaluated less frequently in
patients with PAD. In 1 study, the presence of the lupus
anticoagulant was associated with peripheral atherosclero-
sis.51 Also, markers of platelet activation, such as increases
in beta thromboglobulin levels, are associated with periph-
eral arterial disease.52
Antiplatelet drug therapy. Aspirin is a well-recog-
nized antiplatelet drug that has clear benefits in patients
with cardiovascular diseases. Numerous publications from
the Antithrombotic Trialists’ Collaboration have con-
cluded that patients with cardiovascular disease will realize
a 25% odds reduction in subsequent cardiovascular events
with the use of aspirin.53 This most recent meta-analysis has
also clearly demonstrated that low-dose aspirin (75-160
mg) is protective and probably safer for gastrointestinal
bleeding than higher doses of aspirin. Thus, current recom-
mendations would strongly favor the use of aspirin at a dose
of 81 mg in patients with cardiovascular diseases. What is
remarkable is that specific studies in the PAD population
with aspirin have not shown a statistically significant reduc-
tion in cardiovascular events.54 In the more recent meta-
analysis, when the PAD data were combined from trials
with not only aspirin but also more effective agents such as
also clopidogrel and picotamide, there was a significant 23%
odds reduction in ischemic events.53 Thus, although anti-
platelet drugs are clearly indicated in the overall manage-
ment of PAD, aspirin does not have FDA approval in this
patient population.55
In addition to aspirin, the thienopyridiens are an im-
portant class of antiplatelet agents that have been well
studied in patients with cardiovascular disease. Ticlopidene
has been evaluated in several trials in patients with PAD and
has been found to have benefit in reducing the risk of
myocardial infarction, stroke, and vascular death.56 How-
ever, the clinical usefulness of ticlopidine is limited by
unacceptable adverse effects, such as neutropenia and
thrombocytopenia.57,58 In contrast, Clopidogrel was stud-
ied in the Clopidogrel versus Aspirin in the Prevention of
Recurrent Ischemic Events trial and shown to be highly
effective in the PAD population. The overall benefit in this
particular group was a 24% risk reduction as compared with
the use of aspirin, with a very acceptable safety profile and
only rare reports of thrombotic thrombocytopenia.59,60
Thus, current consensus documents would recommend
Clopidogrel as an important agent in patients with PAD,
which may be more effective than aspirin alone.61
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Recent publications in patients with acute coronary
syndromes suggest that combination therapy with aspirin
and Clopidogrel is more effective than therapy with aspirin
alone, but at a higher risk for major bleeding.62 Whether
combination therapy will be more effective in the PAD
population is currently being studied, but the trial is not
completed.
TREATMENT OF LIMB SYMPTOMS
Exercise rehabilitation for claudication. The use of
a formal exercise program is the best studied and most
effective non-surgical therapy for claudication.63,64 Nu-
merous types of exercise programs have been devised, but
the most successful are supervised in a cardiac rehabilitation
environment and use repeated treadmill walking exercise.65
The initial examination of the patient consists of a clinical
assessment of limitations by using several well-established
questionnaires (eg, Walking Impairment Questionnaire or
Medical Outcomes SF-36).66 Patients should also undergo
an exercise test to maximal claudication pain. The results of
this test are a means of determining the initial training
workload during the rehabilitation program. On comple-
tion of the exercise program, similar evaluations are per-
formed as a means of defining improvements in treadmill
walking distance and questionnaire end points. A typical
supervised exercise program is 60 minutes in duration and
is monitored by a skilled nurse or technician. Patients
should be encouraged to walk primarily on a treadmill
because this most closely reproduces walking in the com-
munity setting. The initial workload of the treadmill is set
to a speed and grade that brings on claudication pain within
3 to 5 minutes. Patients walk at this work rate until they
achieve claudication of moderate severity. They then rest
until the claudication abates, and then resume exercise. On
a weekly basis, patients should be reassessed clinically as
they are able to walk further and further at their chosen
workload. The typical duration of an exercise program is 3
to 6 months. This intervention will allow patients to walk
100% to 150% farther and improve their quality of life.67
Drug therapy for claudication. Vasodilators were an
early class of agents used to treat claudication, but they have
not been shown to have clinical efficacy.68 In 1984, pen-
toxifylline was approved for the treatment of claudication.
In early controlled trials, the drug produced a 12% im-
Evidence-based drug therapy for peripheral arterial disease
Indication Drug Dose Duration Efficacy Safety
CV prevention Aspirin 81 mg/d Life 25% CV risk reduction over placebo in
patients with history of MI or stroke
Peptic ulcer disease
UGI bleed
18% nonsignificant risk reduction in
PAD without prior MI or stroke
Clopidogrel 75 mg/d Life 24% risk reduction over aspirin 325/day Rash
Puritis
Ticlopidine 250 mg BID Life Efficacy similar to clopidogrel Neutropenia
TTP
Ramipril 10 mg/d Life 20% CV risk reduction over placebo Cough
Renal insufficiency
Simvastatin 40 mg/d Life 24% CV risk reduction over placebo Rare myositis
Effective even in PAD with no prior
history of MI or stroke
Rare hepatocellular
toxicity
Effective even if baseline LDL
cholesterol level  116 mg/dl
Bisoprolol 5-10 mg/d Perioperative
period
Reduced risk of perioperative MI and





Graft patency Aspirin 81 mg to
325 mg/d
Life 43% risk reduction in graft occlusion
compared with placebo
As above
Effective in prosthetic grafts
Warfarin INR 3.0 Up to 2 years Effective in vein grafts Higher bleeding
risk
Ticlopidine 250 mg BID Up to 2 years 23% risk reduction in occlusion of vein
grafts over placebo
As above
Claudication Pentoxifyline 400 mg TID Years 0-25% improvement in ACD Nausea
Cilostazol 50 mg to
100 mg
BID





CV, Cardiovascular events including myocardial infarction (MI), stroke (CVA) and vascular death; UGI, upper gastrointestinal; TTP, thrombotic thrombo-
cytopenia; LDL, low density lipoprotein; ACD, absolute (maximal) walking distance on a treadmill.
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provement in the maximal treadmill walking distance.69
However, in a recent study, pentoxifylline was no more
effective than a placebo in improving treadmill walking
distance or functional status assessed by means of question-
naires.70 The results of a meta-analysis concluded that the
drug produced modest increases in treadmill walking dis-
tance as compared with a placebo, but the overall clinical
benefits were questionable.71
Cilostazol is currently the most effective drug for clau-
dication. Approved in 1999, its primary action is to inhibit
phosphodiesterase type 3, which results in vasodilation and
inhibition of platelet aggregation, arterial thromboses, and
vascular smooth muscle proliferation.72-74 In 4 trials of
1534 patients, 100 mg of cilostazol twice daily improved
both pain-free and maximal walking distance, as compared
with a placebo.70,75-77 In 1 trial, 100 mg of cilostazol twice
daily was superior to both a placebo and pentoxifylline.70 In
3 of the trials, cilostazol also improved several aspects of
physical functioning and quality of life as assessed by means
of questionnaires.75-77 The most common adverse effects
of cilostazol are headache, transient diarrhea, palpitations,
and dizziness. Cilostazol should not be given to patients
with claudication who also have heart failure. This is be-
cause of earlier concerns of a mortality risk with the use of
the phosphodiesterase inhibitor class of drugs in patients
with heart failure.78 Currently, data from 2700 patients
treated with cilostazol for claudication and followed for as
long as 6 months have been evaluated. The total cardiovas-
cular morbidity and all-cause mortality rate was 6.5% for
200 mg/d of cilostazol, 6.3% for 100 mg/d of cilostazol,
and 7.7% for placebo.79 These data do not indicate an
increased cardiovascular mortality risk with cilostazol, but
this drug still is labeled with a black box warning from the
FDA about avoiding its use in patients with PAD who also
have any clinical evidence of heart failure.
Clinical trials for treating claudication with additional
drugs are being conducted. Propionyl-L-carnitine is a met-
abolic agent that has been shown to improve treadmill
performance and quality of life in patients with claudica-
tion.80-82 Prostaglandins have been extensively studied in
patients with PAD, but with mixed results. In a recent
study, beraprost, an oral prostaglandin, had positive effects
on treadmill walking distance and quality of life.83 How-
ever, these drugs are still under study, and their usefulness
needs further evaluation.
NONOPERATIVE TREATMENT OF THE
SURGICAL PATIENT
Promoting graft patency. There is evidence that the
use of antiplatelet drugs, particularly aspirin, is good for the
prevention of graft occlusion after peripheral vascular sur-
gical procedures. In the Antithrombotic Trialists’ Collabo-
ration meta-analysis, 3000 patients who underwent periph-
eral artery procedures had a 16% graft occlusion rate with
antiplatelet therapy (principally aspirin), compared with a
25% graft occlusion rate in the control group (P 
.00001).84 Similar to the findings for systemic risk reduc-
tion, low doses of aspirin (50-100 mg) were as effective as
higher doses (900-1000 mg).85,86 Ticlopidine has also
been shown to promote vein graft patency.87
Anticoagulation has also been recommended as an
adjuvant to maintain surgical graft patency. The use of
heparin anticoagulation in the immediate postoperative
period, particularly low-molecular weight heparin, may im-
prove the patency of infrainguinal bypass grafts (vein and
prosthetic), but has also been associated with increased
postoperative bleeding.88,89 The role of long-term oral
anticoagulation is more controversial. In one trial of pa-
tients undergoing infrainguinal bypass graft surgery (in-
cluding the use of vein, prosthetic material, and endarter-
ectomy), the long-term use of coumadin was associated
with an increased bleeding risk, but no benefit in patency or
survival.90 In contrast, another study performed in a similar
population demonstrated that oral anticoagulation im-
proved graft patency, limb salvage, and survival.91 The
benefits were striking; the number of patients that needed
to be treated to prevent 1 occlusion was 6, and the number
needed to be treated to prevent 1 amputation was 7.
Several trials have compared the benefits of anticoagu-
lation with antiplatelet therapy. For example, patients
treated with infrainguinal bypass grafting procedures (pre-
dominantly with prosthetic material) were randomized af-
ter surgery to undergo 3 months treatment with low-
molecular weight heparin or a combination of 300 mg/d of
aspirin and 300 mg/d of dipyridamole.92 The use of low-
molecular weight heparin was associated with better graft
patency, especially in the patients treated for critical leg
ischemia. There were no differences between the groups in
bleeding risk, but there was a non-significant trend for a
higher mortality rate in patients randomized to receive
low-molecular weight heparin.
Perhaps the largest study comparing aspirin to oral
anticoagulation was the Dutch Bypass Oral Anticoagulants
or Aspirin study, performed with 2690 patients undergoing
infrainguinal bypass grafting.93 Half the patients were
treated for claudication, and the other half were treated for
critical leg ischemia, with a fairly even distribution of vein
versus prosthetic material. The aspirin dose was 80 mg/d,
and in patients randomized to anticoagulation, the inter-
national normalized ratio (INR) was maintained at 3.0 to
4.5. The primary end point of patency was equal in the
groups after 21 months of follow-up. However, when the
patients were divided into subgroups according to type of
graft material, anticoagulation maintained vein graft pa-
tency better than aspirin, but at a higher risk of bleeding
complications. In contrast, aspirin maintained prosthetic
graft patency better than anticoagulation. Although sub-
group analyses should be interpreted with caution, these
results were robust and therefore suggest that patients
receiving vein grafts should be preferentially treated with
warfarin, whereas patients receiving grafts of prosthetic
material should be preferentially treated with aspirin.
Oral anticoagulants and aspirin are frequently com-
bined in patients with cardiovascular disease who are at
high risk. In a trial of 56 patients at high risk for graft
failure, all patients received 325 mg/d of aspirin and were
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randomized to receive warfarin to achieve an INR of 2.0 to
3.0.89 After 3 years of follow-up, primary patency, assisted
primary patency, and limb salvage rates were all better in
patients receiving the combination therapy, but they had a
higher risk of bleeding (primarily postoperative wound
hematomas). However, a larger study of 831 patients did
not support the use of aspirin combined with warfarin in
the surgical population.94 In this study, all patients were
given 325 mg/d of aspirin and randomized to a group
receiving warfarin or a control group (INR, 1.4-2.8). All
patients were treated with infrainguinal bypass grafting or
extra-anatomic procedures and observed for as long as 5
years. Patency rates were similar in groups of patients
receiving vein bypass grafts. In the prosthetic bypass graft
group, patency rates were better with combined therapy in
patients who had smaller (6 mm) bypass grafts. Combina-
tion therapy with warfarin and aspirin was significantly
associated with higher mortality rates, but many of the
deaths were caused by cancer, which could not be causally
attributed to the treatment.
In summary, antiplatelet therapy has a clear role in
patients undergoing peripheral vascular bypass graft sur-
gery. This treatment can significantly reduce the risk of
graft occlusion and systemic events of myocardial infarc-
tion, stroke, and vascular death. Adequate comparative
trials have not been performed with aspirin, ticlopidine, and
clopidogrel to determine which drug or combination of
drugs is the best means of maintaining graft patency. Fu-
ture trials are needed to address this issue. Aspirin may be
favored for prosthetic grafts, and anticoagulation may be
favored for vein grafts or for patients who are at a higher risk
for occlusion.95
Preventing cardiac complications of vascular sur-
gery. Patients with PAD who undergo vascular surgery
are at a high risk for cardiovascular complications. This risk
is driven primarily by the extensive nature of their underly-
ing cardiovascular disease.96 Several authors have advo-
cated risk stratification before vascular surgery with a variety
of methods, including clinical assessment and cardiac im-
aging.97 Typical clinical risk factors for major vascular sur-
gery include age 70 years, angina, and a history of myo-
cardial infarction, heart failure, or stroke.98 In patients with
3 risk factors, the use of dobutamine stress echocardiog-
raphy adds predictive value for defining postoperative risk.
However, in most patients with 3 risk factors, cardiac
imaging studies did not add to the risk assessment, and in
these patients, the use of beta-adrenergic blocking drugs
actually predicted a reduced risk of cardiac complications.
Although patients who are at high risk of ischemic events
and may benefit from coronary revascularization may be
identified by means of clinical and imaging strategies before
vascular surgery, there are several limitations to initiating an
extensive cardiac evaluation, including delay or canceling a
critical revascularization procedure.99
Several small, but randomized prospective studies have
evaluated the benefits of beta-adrenergic blockers on re-
ducing cardiac ischemia during and after vascular surgery.
For example, the intravenous administration of esmolol
reduced postoperative cardiac ischemia assessed by means
of Holter monitoring.100 Oral metoprolol before vascular
surgery also reduced cardiac ischemia during surgery.101
These observations led to a randomized trial of bisoprolol
(a selective beta1-adrenergic blocker) in patients at high risk
who were undergoing vascular surgery.102 In this study,
173 patients who had 1 cardiac risk factors and positive
results on a dobutamine stress echocardiography test were
evaluated. These patients were randomized to receive a
drug or placebo, with a primary end point of non-fatal
myocardial infarction or cardiac death at 30 days. Primary
events occurred in 3.4% of the treated group and in 34% of
the placebo group (P  .001; number needed to treat is 3
patients). This same study conducted a 2-year follow-up in
101 patients. The incidence of a cardiac event was 12% in
the treated group and 32% in the placebo group (P .025;
number needed to treat is 5 patients). Thus, the use of a
beta-adrenergic blocker was associated with both short-
term and long-term reductions in cardiac events after major
vascular surgery.
CONCLUSIONS
Patients with PAD are quite common in the office
practice of medicine, yet they are significantly under-recog-
nized and under-treated.103 Patients referred to vascular
surgeons often have the most severe limb manifestations,
years after secondary prevention interventions could have
modified the natural disease history. Thus, a significant
proportion of patients with PAD do not undergo appropri-
ate interventions for reducing their systemic risk, treating
symptoms, and addressing their natural history.
Because of the systemic nature of atherosclerosis, all
patients with PAD, whether they have a history of coronary
disease or not, should be considered for secondary preven-
tion strategies. These include aggressive management of
smoking, treatment of the LDL cholesterol to a level100
mg/dL, treatment of blood pressure to130/85 mm Hg,
and management of diabetes mellitus to a glycohemoglo-
bin level 7.0%. Drugs shown to have particular benefit in
these patients include the statins for LDL reduction, ACE
inhibitors to treat blood pressure, and beta-blockers. In
addition, all patients should be given an antiplatelet drug,
with clopidogrel showing more benefit than aspirin in the
patients with PAD.
Once patients with PAD have been adequately treated
for their systemic risk, those with symptomatic claudication
should also be considered for further medical management.
After an attempt at an exercise program, the only approved
drug with clinically relevant efficacy is cilostazol. A trial of
this drug should be considered, and it should be continued
for at least 3 months before a decision is made about
efficacy. This drug should be avoided in patients with heart
failure.
Patients undergoing vascular surgery or angioplasty,
either for claudication or treatment of critical leg ischemia,
should be treated with antiplatelet drugs to promote the
patency of their revascularization procedures. For this,
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aspirin remains a mainstay of therapy, with newer agents or
combinations of agents still being evaluated.
In summary, pharmacologic management of PAD now
has a critical role to play in all aspects of disease manage-
ment in this patient population. Results of recent trials have
provided new evidence for efficacious therapies for disease
management of PAD.
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